NASDAQ:ENTX

Entera Bio (ENTX) Stock Price, News & Analysis

Entera Bio logo
$3.01 -0.01 (-0.33%)
As of 11:33 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Entera Bio Stock (NASDAQ:ENTX)

Advanced

Key Stats

Today's Range
$3.00
▼
$3.10
50-Day Range
$2.49
▼
$3.25
52-Week Range
$0.91
▼
$4.20
Volume
36,135 shs
Average Volume
938,523 shs
Market Capitalization
$524.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60
Consensus Rating
Moderate Buy

Company Overview

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders.

The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.

Entera Bio’s work is focused on research and clinical development rather than marketing approved medicines. Its programs are intended to address unmet treatment needs in its target conditions.

AI Generated. May Contain Errors.

Entera Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

ENTX MarketRank™: 
2.352043524415 of 5 stars

Entera Bio scored higher than 47% of companies evaluated by MarketBeat, and ranked 588th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Entera Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Entera Bio has a consensus price target of $9.60, representing about 218.9% upside from its current price of $3.01.

  • Amount of Analyst Coverage

    Entera Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Entera Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Entera Bio are expected to grow in the coming year, from ($0.40) to ($0.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Entera Bio is -7.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Entera Bio is -7.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Entera Bio has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.22% of the float of Entera Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Entera Bio has a short interest ratio ("days to cover") of 15.59, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Entera Bio has recently increased by 27.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Entera Bio does not currently pay a dividend.

  • Dividend Growth

    Entera Bio does not have a long track record of dividend growth.

  • News Sentiment

    Entera Bio has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Entera Bio this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for ENTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Entera Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    3.72% of the stock of Entera Bio is held by insiders.

  • Percentage Held by Institutions

    14.11% of the stock of Entera Bio is held by institutions.

  • Read more about Entera Bio's insider trading history.
Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ENTX Stock News Headlines

Entera Bio Ltd. (NASDAQ:ENTX) Stock Has Average Target Price of $9.60
My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
Entera Bio Earnings & Forecasts
Entera Bio (ENTX) Projected to Announce Quarterly Earnings on Friday
See More Headlines

ENTX Stock Analysis - Frequently Asked Questions

Entera Bio's stock was trading at $1.94 at the beginning of the year. Since then, ENTX stock has increased by 55.2% and is now trading at $3.01.

Entera Bio Ltd. (NASDAQ:ENTX) issued its earnings results on Friday, November, 6th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.05.

Entera Bio (ENTX) raised $13 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00-$10.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager.

Top institutional investors of Entera Bio include Nantahala Capital Management LLC (1.73%) and Marshall Wace LLP (0.12%). Insiders that own company stock include Miranda Jayne Toledano, Sean Ellis, Geno J Germano and Haya Taitel.
View institutional ownership trends
.

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include SNDL (SNDL), MARA (MARA), Ocugen (OCGN), NIO (NIO), Riot Platforms (RIOT), AMC Entertainment (AMC) and Bionano Genomics (BNGO).

Company Calendar

Last Earnings
11/06/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ENTX
CIK
1638097
Fax
N/A
Employees
21
Year Founded
2010

Price Target and Rating

High Price Target
$11.00
Low Price Target
$9.00
Potential Upside/Downside
+217.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-38.55%
Return on Assets
-36.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
128.41
Quick Ratio
8.98

Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
13,169.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.58 per share
Price / Book
1.91

Miscellaneous

Outstanding Shares
174,140,000
Free Float
167,660,000
Market Cap
$526.77 million
Optionable
Optionable
Beta
1.48

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:ENTX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners